TARRYTOWN, N.Y., Feb. 17, 2022 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management
participation as follows:
- Cowen 42nd Annual Health Care Conference at
1:30 p.m. ET on Tuesday, March 8,
2022
- Oppenheimer 32nd Annual Healthcare Conference at
10:00 a.m. ET on Tuesday, March 15,
2022
- Barclays Global Healthcare Conference at 8:00 a.m. ET on
Wednesday, March 16, 2022
The sessions may be accessed from the "Investors &
Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations.
Replays of the webcasts will be archived on the Company's website
for at least 30 days.
About Regeneron
Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to nine FDA-approved treatments and numerous
product candidates in development, almost all of which were
homegrown in our laboratories. Our medicines and pipeline are
designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, hematologic conditions, infectious diseases and
rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Contact Information:
Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-announces-investor-conference-presentations-301484955.html
SOURCE Regeneron Pharmaceuticals, Inc.